A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants

Healthy Clinical Trial

Official title:

A Single-center, Open-label, Single-dose, Randomized, 3-way Crossover Phase 1 Study in Healthy Adult Participants to Assess the Relative Oral Bioavailability of Macitentan 75 mg as Two Different Test Formulations Compared to the Reference Formulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05392530
• Other study ID #: CR109202
• Secondary ID: 2022-000275-3967
• Status: Completed
• Phase: Phase 1
• Start date: May 25, 2022
• Est. completion date: September 14, 2022

Study information

• Verified date: November 2022
• Source: Actelion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the rate and extent of absorption of a single oral dose of macitentan given as 2 test formulations compared to the reference formulation under fed conditions in healthy adult participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: September 14, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy on the basis of physical examination and medical and surgical history, performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
• Systolic blood pressure (SBP) between 100 and 145 millimeters of mercury (mmHg) (inclusive), diastolic blood pressure (DBP) between 50 and 90 mmHg (inclusive), and pulse rate between 45 and 90 beats per minute (inclusive), within 3 minutes after standing up and after the participant is supine for at least 5 minutes, at screening
• Twelve-lead electrocardiogram (ECG) without clinically relevant abnormalities, at the discretion of the investigator, measured after the participant is supine for at least 5 minutes, at screening
• Body weight not less than 50 kilograms (Kg) and body mass index (BMI; weight/height^2) within the range 18.5 -30 kg per meter square (kg/m^2) (inclusive)at screening
• All women must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening and a negative urine pregnancy test on Day -1 of the first treatment period

Exclusion Criteria:

• Known allergies, hypersensitivity, or intolerance to any active substance or drugs of the same class, or any excipient of the drug formulation(s)
• History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the study intervention(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed)
• A history of repeated fainting due to cardiac cause, collapse, syncope, orthostatic hypotension, or vasovagal reactions
• Female participant who is breastfeeding at screening and plans to breastfeed throughout the study
• Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Macitentan
Macitentan film coated tablets will be administered orally as per assigned treatment sequence.

Locations

Country	Name	City	State
Belgium	SGS Belgium NV	Edegem

Sponsors (1)

Lead Sponsor	Collaborator
Actelion

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Analyte Concentration (Cmax) of Macitentan	Cmax is defined as maximum observed plasma analyte concentration of macitentan.	Predose, up to 336 hours post dose (up to Day 15)
Primary	Area Under the Plasma Analyte Concentration-time Curve from Time Zero to Time of the Last Quantifiable Concentration of Macitentan (AUC[0-last])	AUC(0-last) is defined as area under the plasma analyte concentration-time curve of macitentan from time zero to time of the last quantifiable (non-below quantification limit [BQL]) concentration.	Predose, up to 336 hours post dose (up to Day 15)
Primary	Area Under the Plasma Analyte Concentration-time Curve from Time Zero to Infinite Time (AUC[0-infinity]) of Macitentan	AUC(0-infinity) is defined as area under the plasma analyte concentration-time curve of macitentan from time zero to infinite time.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Actual Sampling Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax) of Macitentan and its Metabolite Aprocitentan	Tmax is defined as actual sampling time to reach the maximum observed plasma analyte concentration of macitentan and its metabolite aprocitentan.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Last Observed Measurable Plasma Analyte Concentration (Clast) of Macitentan and its Metabolite Aprocitentan	Clast is defined as last observed measurable plasma analyte concentration of macitentan and its metabolite aprocitentan.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Area Under the Plasma Analyte Concentration-time Curve of Macitentan and its Metabolite Aprocitentan from Time Zero to 72 Hours Post dose (AUC[0-72 Hours])	AUC(0-72 hours) is defined as area under the plasma analyte concentration-time curve of macitentan and its metabolite aprocitentan from time zero to 72 hours post dose, calculated by linear-linear trapezoidal summation.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Apparent Terminal Elimination Half-life (t1/2) of Macitentan and its Metabolite Aprocitentan	t1/2 is defined as apparent terminal elimination half-life of macitentan and its metabolite aprocitentan.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Apparent Terminal Elimination Rate Constant (Lambda[z]) of Macitentan and its Metabolite Aprocitentan	Lambda(z) is defined as apparent terminal elimination rate constant of macitentan and its metabolite aprocitentan, estimated by linear regression using the terminal log-linear phase of the log transformed concentration versus time curve.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Total Apparent Oral Clearance (CL/F) of Macitentan	CL/F of macitentan is defined as total apparent oral clearance, calculated as dose/AUC (0-infinity).	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Apparent Volume of Distribution (Vdz/F) of Macitentan	Vdz/F of macitentan is defined as apparent volume of distribution, calculated as dose/(Lambda[z]*AUC [0-infinity]).	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Maximum Observed Plasma Analyte Concentration (Cmax) of Aprocitentan	Cmax is defined as maximum observed plasma analyte concentration of metabolite aprocitentan.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Area Under the Plasma Analyte Concentration-Time Curve from Time Zero to Time of the Last Quantifiable Concentration of Aprocitentan (AUC[0-last])	AUC(0-last) of metabolite Aprocitentan is defined as area under the plasma analyte concentration-time curve from time zero to time of the last quantifiable (BQL) concentration, calculated by linear-linear trapezoidal summation.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Area Under the Plasma Analyte Concentration-Time Curve of Aprocitentan from Time Zero to Infinity (AUC[0-infinity])	AUC(0-infinity) is defined as area under the plasma analyte concentration-time curve of metabolite aprocitentan from time zero to infinite time.	Predose, up to 336 hours post dose (up to Day 15)
Secondary	Number of Participants with Serious Adverse Events (SAEs)	Number of Participants with Serious Adverse Events (SAEs) will be reported SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.	Up to 13 weeks
Secondary	Number of Participants with Adverse Events (AEs)	Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product.	Up to 13 weeks
Secondary	Number of Participants with Abnormalities in Physical Examination	Number of participants with abnormalities in physical examination (including general appearance, respiratory, neurological, eyes, ear/nose/throat, thyroid, cardiovascular, abdominal/gastrointestinal, hepatic, musculoskeletal, and dermatologic) will be reported.	Up to Day 15
Secondary	Number of Participants with Abnormalities in Vital Signs	Number of participants with abnormalities in vital signs (including temperature [tympanic], pulse rate, and blood pressure) will be reported.	Up to Day 15
Secondary	Number of Participants with Abnormalities in Electrocardiograms (ECGs)	Number of participants with abnormalities in ECGs will be reported.	Up to Day 15
Secondary	Number of Participants with Abnormalities in Clinical Laboratory Tests	Number of participants with abnormalities in clinical laboratory tests (including serum chemistry, hematology, and urinalysis) will be reported.	Up to Day 15